A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity - PubMed (original) (raw)
doi: 10.1038/nchembio.90. Epub 2008 May 11.
Barbara Valsasina, Valter Croci, Maria Menichincheri, Sonia Rainoldi, Vanessa Marchesi, Marcello Tibolla, Pierluigi Tenca, Deborah Brotherton, Clara Albanese, Veronica Patton, Rachele Alzani, Antonella Ciavolella, Francesco Sola, Antonio Molinari, Daniele Volpi, Nilla Avanzi, Francesco Fiorentini, Marina Cattoni, Sandra Healy, Dario Ballinari, Enrico Pesenti, Antonella Isacchi, Jurgen Moll, Aaron Bensimon, Ermes Vanotti, Corrado Santocanale
Affiliations
- PMID: 18469809
- DOI: 10.1038/nchembio.90
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity
Alessia Montagnoli et al. Nat Chem Biol. 2008 Jun.
Abstract
Cdc7 is an essential kinase that promotes DNA replication by activating origins of replication. Here, we characterized the potent Cdc7 inhibitor PHA-767491 (1) in biochemical and cell-based assays, and we tested its antitumor activity in rodents. We found that the compound blocks DNA synthesis and affects the phosphorylation of the replicative DNA helicase at Cdc7-dependent phosphorylation sites. Unlike current DNA synthesis inhibitors, PHA-767491 prevents the activation of replication origins but does not impede replication fork progression, and it does not trigger a sustained DNA damage response. Treatment with PHA-767491 results in apoptotic cell death in multiple cancer cell types and tumor growth inhibition in preclinical cancer models. To our knowledge, PHA-767491 is the first molecule that directly affects the mechanisms controlling initiation as opposed to elongation in DNA replication, and its activities suggest that Cdc7 kinase inhibition could be a new strategy for the development of anticancer therapeutics.
Comment in
- Stopping replication, at the beginning.
Jackson PK. Jackson PK. Nat Chem Biol. 2008 Jun;4(6):331-2. doi: 10.1038/nchembio0608-331. Nat Chem Biol. 2008. PMID: 18488006 No abstract available.
Similar articles
- Stopping replication, at the beginning.
Jackson PK. Jackson PK. Nat Chem Biol. 2008 Jun;4(6):331-2. doi: 10.1038/nchembio0608-331. Nat Chem Biol. 2008. PMID: 18488006 No abstract available. - Cdc7 as a potential new target for cancer therapy.
Ito S, Taniyami C, Arai N, Masai H. Ito S, et al. Drug News Perspect. 2008 Nov;21(9):481-8. doi: 10.1358/dnp.2008.21.9.1290818. Drug News Perspect. 2008. PMID: 19180266 Review. - Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.
Vanotti E, Amici R, Bargiotti A, Berthelsen J, Bosotti R, Ciavolella A, Cirla A, Cristiani C, D'Alessio R, Forte B, Isacchi A, Martina K, Menichincheri M, Molinari A, Montagnoli A, Orsini P, Pillan A, Roletto F, Scolaro A, Tibolla M, Valsasina B, Varasi M, Volpi D, Santocanale C. Vanotti E, et al. J Med Chem. 2008 Feb 14;51(3):487-501. doi: 10.1021/jm700956r. Epub 2008 Jan 18. J Med Chem. 2008. PMID: 18201066 - First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
Menichincheri M, Bargiotti A, Berthelsen J, Bertrand JA, Bossi R, Ciavolella A, Cirla A, Cristiani C, Croci V, D'Alessio R, Fasolini M, Fiorentini F, Forte B, Isacchi A, Martina K, Molinari A, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pezzetta D, Pillan A, Poggesi I, Roletto F, Scolaro A, Tatò M, Tibolla M, Valsasina B, Varasi M, Volpi D, Santocanale C, Vanotti E. Menichincheri M, et al. J Med Chem. 2009 Jan 22;52(2):293-307. doi: 10.1021/jm800977q. J Med Chem. 2009. PMID: 19115845 - Targeting cell division cycle 7 kinase: a new approach for cancer therapy.
Montagnoli A, Moll J, Colotta F. Montagnoli A, et al. Clin Cancer Res. 2010 Sep 15;16(18):4503-8. doi: 10.1158/1078-0432.CCR-10-0185. Epub 2010 Jul 20. Clin Cancer Res. 2010. PMID: 20647475 Review.
Cited by
- Use of Mitotic Protein Kinase Inhibitors and Phospho-Specific Antibodies to Monitor Protein Phosphorylation During the Cell Cycle.
Nasa I, Moorhead GB, Kettenbach AN. Nasa I, et al. Methods Mol Biol. 2021;2329:205-221. doi: 10.1007/978-1-0716-1538-6_15. Methods Mol Biol. 2021. PMID: 34085225 - Uncovering potential CDK9 inhibitors from natural compound databases through docking-based virtual screening and MD simulations.
Singh P, Kumar V, Jung TS, Lee JS, Lee KW, Hong JC. Singh P, et al. J Mol Model. 2024 Jul 16;30(8):267. doi: 10.1007/s00894-024-06067-z. J Mol Model. 2024. PMID: 39012568 - Crystal structure of human CDC7 kinase in complex with its activator DBF4.
Hughes S, Elustondo F, Di Fonzo A, Leroux FG, Wong AC, Snijders AP, Matthews SJ, Cherepanov P. Hughes S, et al. Nat Struct Mol Biol. 2012 Nov;19(11):1101-7. doi: 10.1038/nsmb.2404. Epub 2012 Oct 14. Nat Struct Mol Biol. 2012. PMID: 23064647 - A genetic screen for replication initiation defective (rid) mutants in Schizosaccharomyces pombe.
Locovei AM, Yin L, D'Urso G. Locovei AM, et al. Cell Div. 2010 Aug 27;5:20. doi: 10.1186/1747-1028-5-20. Cell Div. 2010. PMID: 20799962 Free PMC article. - Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation.
Liu HY, Tuckett AZ, Fennell M, Garippa R, Zakrzewski JL. Liu HY, et al. Invest New Drugs. 2018 Aug;36(4):590-600. doi: 10.1007/s10637-017-0557-6. Epub 2018 Jan 3. Invest New Drugs. 2018. PMID: 29297149 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous